Factors predictive of successful darunavir/ritonavir-based therapy in highly antiretroviral-experienced HIV-1-infected patients (the DARWEST study)

Journal of Clinical Virology

Volumn 47, Issue 3, 2010, Pages 248-252

  Delaugerre, C ^a   Buyck, J F ^b   Peytavin, G ^c   Viard, J P ^d   Chaix, M L ^d   Zucman, D ^e   Mortier, E ^f   Blanche, S ^d   Rouveix, E ^b   Force, G ^g   Aegerter, P ^b   de Truchis, P ^h  

^a SAINT LOUIS HOSPITAL   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c BICHAT HOSPITAL   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e FOCH HOSPITAL   (France)

^f HÔPITAL LOUIS MOURIER   (France)

^g Perpetuel Secours Hospital   (France)

^h RAYMOND POINCARÉ HOSPITAL   (France)

Author keywords

Darunavir; Enfuvirtide; Etravirine; HIV; Raltegravir; Triple class drug resistance

Indexed keywords

DARUNAVIR PLUS RITONAVIR; ENFUVIRTIDE; ETRAVIRINE; RALTEGRAVIR;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CROSS RESISTANCE; DRUG EFFICACY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; SALVAGE THERAPY; TREATMENT RESPONSE; VIROLOGY; VIRUS LOAD; VIRUS MUTATION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RITONAVIR; SULFONAMIDES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 76449109384     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2009.12.022     Document Type: Article

References (26)

1. De Meyer S., Azijn H., Surleraux D., Jochmans D., Tahri A., Pauwels R., et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 49 (2005) 2314-2321
2. Dierynck I., De Wit M., Gustin E., Keuleers I., Vandersmissen J., Hallenberger S., et al. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier. J Virol 81 (2007) 13845-13851
3. Clotet B., Bellos N., Molina J.M., Cooper D., Goffard J.C., Lazzarin A., et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 369 (2007) 1169-1178
4. Molina J.M., Cohen C., Katlama C., Grinsztejn B., Timerman A., Pedro Rde J., et al. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3. J Acquir Immune Defic Syndr 46 (2007) 24-31
5. Johnson V.A., Brun-Vezinet F., Clotet B., Gunthard H.F., Kuritzkes D.R., Pillay D., et al. Update of the drug resistance mutations in HIV-1: spring 2008. Top HIV Med 16 (2008) 62-68
6. de Meyer S., Vangeneugden T., van Baelen B., de Paepe E., van Marck H., Picchio G., et al. Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses 24 (2008) 379-388
7. Maguire M., Shortino D., Klein A., Harris W., Manohitharajah V., Tisdale M., et al. Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. Antimicrob Agents Chemother 46 (2002) 731-738
8. Tie Y., Boross P.I., Wang Y.F., Gaddis L., Hussain A.K., Leshchenko S., et al. High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. J Mol Biol 338 (2004) 341-352
9. Lederman M.M., Miller V., Weller I., and Deeks S.G. A new approach for 'deep salvage' trials in advanced HIV infection. Aids 21 (2007) 1503-1506
10. Cooper D.A., Steigbigel R.T., Gatell J.M., Rockstroh J.K., Katlama C., Yeni P., et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 359 (2008) 355-365
11. Dejesus E., Gottlieb M.S., Gathe Jr. J.C., Greenberg M.L., Guittari C.J., and Zolopa A.R. Safety and efficacy of enfuvirtide in combination with darunavir/ritonavir and an optimized background regimen in triple-class experienced HIV-Infected patients: the BLQ study. Antimicrob Agents Chemother (2008)
12. Lazzarin A., Campbell T., Clotet B., Johnson M., Katlama C., Moll A., et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 370 (2007) 39-48
13. Madruga J.V., Berger D., McMurchie M., Suter F., Banhegyi D., Ruxrungtham K., et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced. HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 370 (2007) 49-58
14. Yasdanpanah Y., Fagard C., Descamps D., Taburet A.M., Roquebert B., Tschope I., et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of he ANRS 139 TRIO trial. Clin Infect Dis 49 (2009) 1441-1449
15. De Meyer S., Dierynck I., Lathouwers E., Van Baelen B., Vangeneugden T., Spinosa-Guzman S., et al. Phenotypic and genotypic determinants of resistance to darunavir: analysis of data from treatment-experienced patients in POWER 1,2,3 and DUET-1 and 2. XVII international HIV drug resistance. Sitges, Spain (2008)
16. Descamps D., Lambert-Niclot S., Marcelin A.G., Peytavin G., Roquebert B., Katlama C., et al. Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients. J Antimicrob Chemother 63 (2009) 585-592
17. Pellegrin I., Wittkop L., Joubert L.M., Neau D., Bollens D., Bonarek M., et al. Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study). Antivir Ther 13 (2008) 271-279
18. Molto J., Santos J.R., Perez-Alvarez N., Cedeno S., Miranda C., Khoo S., et al. Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients. Antimicrob Agents Chemother 52 (2008) 3928-3932
19. Delaugerre C., Pavie J., Palmer P., Ghosn J., Blanche S., Roudiere L., et al. Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen. Aids 22 (2008) 1809-1813
20. Lambert-Niclot S., Flandre P., Canestri A., Peytavin G., Blanc C., Agher R., et al. Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir. Antimicrob Agents Chemother 52 (2008) 491-496
21. Delaugerre C., Mathez D., Peytavin G., Berthe H., Long K., Galperine T., et al. Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients. Aids 21 (2007) 1210-1213
22. Garrido C., Poveda E., Corral A., De Mendoza C., and Soriano V. Low rate of tipranavir and darunavir resistance mutations in PI-experienced patients using the new interpretation scores - implications for PI sequencing. XVII international HIV drug resistance. Sitges, Spain (2008)
23. Hall D.B., Baxter J., Schapiro J., Boucher C.A.B., Tilke C., and Scherer J. Mutations selected by other protease inhibitors predict durable response to tipranavir in treatment-experienced patients. XVII international HIV drug resistance. Sitges, Spain (2008)
24. Spagnuolo V., Gianotti N., Seminari E., Galli L., Fusetti G., Salpietro S., et al. Changes in darunavir/r resistance score after previous failure to tipranavir/r in HIV-1-infected multidrug-resistant patients. J Acquir Immune Defic Syndr 50 (2009) 192-195
25. Sekar V.S., De Meyer S., Vangeneugden T., Lefebvre E., De Pauw M., Van Baelen B., et al. Pharmacokinetic/pharmacodynamic (PK/PD) analyses of TMC 114 in the POWER 1 and POWER 2 trials in treatment-experienced HIV-Infected patients. Proceedings of the 13th conference on retroviruses and opportunistic infections. Denver, USA (2006)
26. Sekar V.S., De Meyer S., Vangeneugden T., Lefebvre E., De Pauw M., Van Baelen B., et al. Absence of TMC114 exposure-efficacy and exposure-safety relationships in POWER 3. Proceedings of the 16th international AIDS conference. Toronto, Canada (2006)